英美合作基因工程: 亞麻薺之長鏈奧米加-3(鱼油替代)工程
Source: Wikipedia
轉載自:
Rothamsted
Research Licenses Agragen Patent for Transformation of Camelina to Make Omega-3
Fatty Acids
NEWS
PROVIDED BY
21
Nov, 2016,
CINCINNATI,
Nov. 21, 2016 /PRNewswire/ -- Agragen, LLC, a
Cincinnati-based plant sciences company, announces the licensing of their patent
for the transformation of camelina sativa to Rothamsted Research of Harpenden,
Hertfordshire, Great Britain, which enables Rothamsted to continue to produce
long chain omega-3 fatty acids in camelina.
Rothamsted is developing a camelina that will produce
the same bioactive omega-3 fatty acids found in fish oil using this licensed
technology from Agragen.
"We had been in negotiations for some time regarding the
use of our patent with Rothamsted to permit them to transform camelina, which is
an essential step to make these omega-3 fatty acids. This license gives them
the freedom to operate to transform camelina," said Sam Huttenbauer, Jr., chief
development officer of Agragen. "Licensing this technology by Rothamsted will
not alter our own efforts to make these omega-3 fatty acids in camelina, a long
held goal of Agragen."
"Agragen believes that collaborations that advance
science will move the use of camelina forward, enabling the further
establishment of this crop," said Eric J. Murphy, chief science officer,
Agragen. "It's gratifying to know our technology will be used to further
Rothamsted's efforts to find a renewable source for these fatty acids that are
critical for human health."
Agragen recently licensed technology from The University of Hong Kong (Mee Len Chye 蔡美蓮 , Wallace Lim 林文量) for their own efforts to make a high yield camelina that produces
fatty acids found in fish oil.
"Agragen believes that combining this technology with
our own omega-3 program will produce a camelina with twice the yield of
traditional camelina", said Murphy. "Using our elite lines of camelina with
this technology will give us a significant competitive advantage in production
of omega-3 camelina that will require fewer acres."
"There is a substantial need to produce a sustainable
source of marine derived omega-3 fatty acids and with the size of the market,
licensing our patent for the transformation of camelina to Rothamsted Research
just makes sense," said Murphy. "In the end, this will only propel own efforts
forward in this space."
Agragen,
LLC is a Cincinnati, Ohio-based plant sciences company focused on using
Camelina
sativa as
a platform to produce fatty acids for use in human health and disease as well as
a sustainable feedstock for bio-derived jet fuel.
沒有留言:
張貼留言